Increased B-cell Activating Factor Levels in Children with Acute Brucellosis

Key Findings & Data:We aimed to show the association of serum ‘A PRoliferation-Inducing Ligand (APRIL) (TNFSF13A)’ and ‘B-cell Activating Factor (BAFF)’ levels belonging to the tumor necrosis factor family in children with acute brucellosis.

💡

Conclusion & Impact:BAFF levels were significantly higher in children with acute brucellosis than the control group (548.6±253.4 vs. 280.5±83.6, p

🔬Design:Research Article

📍Scope:2018 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: Brucellosis is a chronic infectious disease. We aimed to show the association of serum ‘A PRoliferation-Inducing Ligand (APRIL) (TNFSF13A)’ and ‘B-cell Activating Factor (BAFF)’ levels belonging to the tumor necrosis factor family in children with acute brucellosis. Methods: Fifty children with acute brucellosis and 35 healthy controls who were admitted during a two-year period between 2018 and 2020 were prospectively included in the study. All patients and healthy children were tested for complete blood counts, C-reactive protein, BAFF, and APRIL levels, and erythrocyte sedimentation rate. Results: The mean age of 50 patients with acute brucellosis was 10.2±3.6 years, and 37 (74%) of them was male. BAFF levels were significantly higher in children with acute brucellosis than the control group (548.6±253.4 vs. 280.5±83.6, p

🔖

Cite This Article

ÇEVİK, Ö., ERDENİZ, E. H. (2022). Increased B-cell Activating Factor Levels in Children with Acute Brucellosis. Trends in pediatrics, Cilt: 1 - Sayı: 1, 11–16. https://ajindex.com/articles/598919

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (13)

Young EJ. Brucella Species (Brucellosis). In: Long SS, Prober CG, Fischer M (eds). Principles and Practice of Pediatric Infectious Diseases. Philadelphia, Elsevier, 2017;886-9.
Kara SS, Polat M, Tapisiz A, Tezer H, İlhan Demir P. Brucella spondylodiscitis: A Case Report. GMJ. 2013;24:23-5
Polat M, Kara SS, Tirhiş O, Tapisiz A, Tezer H. A case of fever of unknown origin with brucellosis and the prozone phenomenon. Turkish J Pediatr Dis. 2013;7:29- 31.
Parlak M, Akbayram S, Doğan M, et al. Clinical manifestations and laboratory findings of 496 children with brucellosis in Van, Turkey. Pediatr Int. 2015;57(4):586-9.
Bosilkovski M, Krteva L, Caparoska S, Labacevski N, Petrovski M. Childhood brucellosis: Review of 317 cases. Asian Pac J Trop Med. 2015;8(12):1027-32.
Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: who’s who?. Autoimmun Rev. 2008;7(4):267-71.
Pranzatelli MR, Tate ED, McGee NR, et al. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflammation. 2013;10:10.
George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther. 2008;10(4):R97.
Planelles L, Medema JP, Hahne M, Hardenberg G. The expanding role of APRIL in cancer and immunity. Curr Mol Med. 2008;8(8):829-44.
Tecchio C, Nichele I, Mosna F, et al. A proliferationinducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia. Eur J Haematol. 2011;87(3):228- 34.
Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24(3):203-15.
Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829-34.
Doi M, Takeda T, Sakurai Y, et al. Altered immunoglobulin A and M